Tag Archives: Difei Yang

Mizuho Securities Reaffirms Their Buy Rating on Concert Pharma (CNCE)

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Concert Pharma (CNCE – Research Report), with a price target of $18.00. The company’s shares closed last Thursday at $10.27. According to TipRanks.com, Yang ‘s

Analysts’ Top Healthcare Picks: Sarepta Therapeutics (SRPT), Johnson & Johnson (JNJ)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), Johnson & Johnson (JNJ – Research Report) and Palatin Technologies (PTN – Research Report) with bullish

Mizuho Securities Reaffirms Their Buy Rating on Avrobio (AVRO)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Avrobio (AVRO – Research Report) on September 12 and set a price target of $35.00. The company’s shares closed last Monday at $15.53. According to TipRanks.com, Yang is currently ranked

Mizuho Securities Maintains a Buy Rating on Concert Pharma (CNCE)

In a report issued on September 12, Difei Yang from Mizuho Securities maintained a Buy rating on Concert Pharma (CNCE – Research Report), with a price target of $18.00. The company’s shares closed last Friday at $10.01. According to TipRanks.com,

Mizuho Securities Maintains Their Buy Rating on Akebia Therapeutics (AKBA)

Mizuho Securities analyst Difei Yang maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price target of $17.00. The company’s shares closed last Monday at $10.67. According to TipRanks.com, Yang is currently ranked with

Analysts Have Conflicting Sentiments on These Healthcare Companies: Xeris Pharmaceuticals (NASDAQ: XERS) and Evolus (NASDAQ: EOLS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Xeris Pharmaceuticals (XERS – Research Report) and Evolus (EOLS – Research Report). Xeris Pharmaceuticals (XERS) In a report released today, Difei Yang from Mizuho Securities